GNFT

Genfit SA

Add to Watchlist

Advanced Chart

4.120

-0.035(-0.842%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.190

Open

4.190

VWAP

Vol

940.00

Mkt Cap

206.01M

Low

4.010

Amount

EV/EBITDA(TTM)

32.15

Total Shares

49.86M

159.55M

EV/OCF(TTM)

10.50

P/S(TTM)

2.79

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Valuation Metrics

The current forward P/E ratio for Genfit SA (GNFT.O) is -4.16, compared to its 5-year average forward P/E of -0.85. For a more detailed relative valuation and DCF analysis to assess Genfit SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.85

Current PE

-4.16

Overvalued PE

12.51

Undervalued PE

-14.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

1.00

Current EV/EBITDA

59.56

Overvalued EV/EBITDA

12.79

Undervalued EV/EBITDA

-10.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

6.36

Current PS

2.07

Overvalued PS

12.43

Undervalued PS

0.29